Abstract
Angiopoietin-related growth factor (AGF) was recently introduced as a novel liver-derived
protein that antagonizes obesity and insulin resistance. In the current study, we
investigated circulating AGF levels in relation to renal function and type 2 diabetes
mellitus (T2DM). Angiopoietin-related growth factor was determined by enzyme-linked
immunosorbent assay in subjects with a glomerular filtration rate greater than 50
mL/min (n = 60, 30 diabetic and 30 nondiabetic) and in patients on chronic hemodialysis
(CD; n = 60, 32 diabetic and 28 nondiabetic). Furthermore, AGF was correlated to clinical
and biochemical measures of renal function, glucose and lipid metabolism, as well
as inflammation. Median serum AGF levels were significantly lower in CD patients (125.9
± 96.3 μg/L) as compared with subjects with a glomerular filtration rate greater than 50 mL/min
(164.0 ± 95.4 μg/L) (P < .05). Furthermore, AGF serum levels were significantly increased in diabetic patients
(161.7 ± 114.2 μg/L) as compared with nondiabetic subjects (123.0 ± 88.2 μg/L) (P < .01). Moreover, CD negatively and T2DM positively predicted AGF concentrations
in multiple regression analysis. In addition, fasting serum glucose was independently
and positively correlated with circulating AGF in all patients and controls. Our results
suggest that renal dysfunction is negatively and T2DM is positively associated with
AGF serum levels. Further studies are needed to better elucidate the physiologic significance
of circulating AGF in human disease.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Metabolism - Clinical and ExperimentalAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Regulation of adipocytokines and insulin resistance.Diabetologia. 2003; 46: 1594-1603
- Adipose tissue–derived factors: impact on health and disease.Endocr Rev. 2006; 27: 762-778
- Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.Science. 1993; 259: 87-91
- FGF-21 as a novel metabolic regulator.J Clin Invest. 2005; 115: 1627-1635
- Angiopoietin-related growth factor antagonizes obesity and insulin resistance.Nat Med. 2005; 11: 400-408
- Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.J Am Soc Nephrol. 2002; 13: 134-141
- Increased plasma leptin concentration in end-stage renal disease.J Clin Endocrinol Metab. 1997; 82: 847-850
- Serum levels of the adipokine vaspin in relation to metabolic and renal parameters.J Clin Endocrinol Metab. 2008; 93: 247-251
- Serum levels of the adipokine RBP-4 in relation to renal function.Diabetes Care. 2007; 30: 2588-2592
- Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.Diabetologia. 1985; 28: 412-419
- A rapid, quantitative immunofunctional assay for measuring human leptin.Horm Res. 2002; 57: 127-132
- Candidate genes for obesity revealed from a C57BL/6J x 129S1/SvImJ intercross.Int J Obes (Lond). 2008; 32: 1180-1189
- Angiopoietin-related growth factor suppresses gluconeogenesis through the Akt/forkhead box class O1-dependent pathway in hepatocytes.J Pharmacol Exp Ther. 2007; 323: 787-793
- The role of leptin in leptin resistance and obesity.Physiol Behav. 2006; 88: 249-256
Article info
Publication history
Accepted:
November 18,
2008
Received:
July 3,
2008
Identification
Copyright
© 2009 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
